Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

AIM To explore the effect of histone deacetylase inhibitor, trichostatin A (TSA) on the growth of biliary tract cancer cell lines (gallbladder carcinoma cell line and cholangiocarcinoma cell line) in vivo and in vitro, and to investigate the perspective of histone deacetylase inhibitor in its clinical application. METHODS The survival rates of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) treated with various doses of TSA were detected by methylthiazoy tetrazolium (MTT) assay. A nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, and changes in the growth of transplanted tumor after treated with TSA were measured. RESULTS TSA could inhibit the proliferation of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) in a dose-dependent manner. After the nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, the growth of cancer was inhibited in the model after treated with TSA. CONCLUSION TSA can inhibit the growth of cholangiocarcinoma and gallbladder carcinoma cell lines in vitro and in vivo.

• Publication year

  2008

• Venue

  World Journal of Gastroenterology

• Publication date

  2008-04-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3748/WJG.14.2578PMID 18442209PMCID PMC2708373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• “Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review” [Cancer Treatment Reviews 32(5) (2006) 333–347]

  2007cited by this paper
• Development of histone deacetylase inhibitors for cancer treatment

  2007cited by this paper
• Cancer as a manifestation of aberrant chromatin structure.

  2007cited by this paper
• Cancer Susceptibility: Epigenetic Manifestation of Environmental Exposures

  2007cited by this paper
• Epigenetic control of tumor suppression.

  2007cited by this paper
• HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

  2007cited by this paper
• Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A

  2007cited by this paper
• Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

  2007cited by this paper
• Treatment of Early Non-Small Cell Lung Cancer, Stage IA, by Image-Guided Robotic Stereotactic Radioablation—CyberKnife

  2007cited by this paper
• Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.

  2007cited by this paper
• Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997–2002

  2007cited by this paper
• Histone deacetylase inhibitors in cancer therapy

  2007cited by this paper
• Stage specific expression of histone deacetylase 4 (HDAC4) during oogenesis and early preimplantation development in mice.

  2006cited by this paper
• Enhanced histone acetylation and transcription: a dynamic perspective.

  2006cited by this paper
• Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

  2006cited by this paper
• The genetic differences between gallbladder and bile duct cancer cell lines.

  2006cited by this paper
• Chromatin remodelling and chromosome damage distribution

  2006cited by this paper
• Chromatin remodelling: the industrial revolution of DNA around histones

  2006cited by this paper
• Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor–Positive Prostate Cancer Cells

  2006cited by this paper
• SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.

  2006cited by this paper
• Bile Acid Analysis in Biliary Tract Cancer

  2006cited by this paper
• Statistical assessment of the global regulatory role of histone acetylation in Saccharomyces cerevisiae

  2006cited by this paper
• Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

  2006cited by this paper
• Targeting histone deacetylase in cancer therapy

  2006cited by this paper
• Indication of Hepatopancreatoduodenectomy for Biliary Tract Cancer

  2006cited by this paper
• Histone Deacetylase Inhibitors for Cancer Therapy

  2006cited by this paper
• Chemoradiotherapy in gallbladder cancer

  2006cited by this paper
• [Biliary tract cancer: present status in early diagnosis and treatment].

  2006cited by this paper
• Perioperative Synbiotic Treatment to Prevent Postoperative Infectious Complications in Biliary Cancer Surgery: A Randomized Controlled Trial

  2006cited by this paper
• The necessity of a human epigenome project.

  2006cited by this paper
• Chromatin remodeling, cancer and chemotherapy.

  2006cited by this paper
• Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib

  2006cited by this paper
• Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.

  2006cited by this paper
• A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

  2006cited by this paper
• [A survey on the diagnosis and treatment of biliary tract cancers in Shanghai].

  2005cited by this paper
• Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy

  2005cited by this paper
• Biliary tract cancers: current concepts and controversies

  2005cited by this paper
• Translating the Histone Code

  2001cited by this paper

• HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer

  2021cites this paper
• The Investigative Therapeutic Pipeline for Cholangiocarcinoma: Insights from Model Systems

  2021cites this paper
• The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review)

  2019cites this paper
• The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

  2017cites this paper
• CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway

  2017cites this paper
• ЖЕЛЧНОКАМЕННАЯ БОЛЕЗНЬ: ЭПИДЕМИОЛОГИЯ, ФАКТОРЫ РИСКА, ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ, ПРОФИЛАКТИКА

  2016cites this paper
• Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance

  2016cites this paper
• TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4

  2015cites this paper
• KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9.

  2014cites this paper
• Rôle du microenvironnement dans la progression du cholangiocarcinome intrahépatique : mécanismes moléculaires impliqués et recherche de biomarqueurs pronostiques.

  2014cites this paper
• The significance of genetics for cholangiocarcinoma development.

  2013cites this paper
• Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma

  2013cites this paper
• Sodium Valproate Inhibits the Growth of Human Cholangiocarcinoma In Vitro and In Vivo

  2013cites this paper
• Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma.

  2013cites this paper
• Epigenetics in Cholangiocarcinoma

  2012cites this paper
• Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma

  2010cites this paper
• Liver transplantation for non–hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature

  2010cites this paper
• Genetic and epigenetic alterations are involved in the regulation of TPM 1 in cholangiocarcinoma

  year unknowncites this paper